% | $
Quotes you view appear here for quick access.

Dendreon Anonim Ortaklik Message Board

  • rvajr1932 rvajr1932 Apr 20, 2009 9:12 AM Flag


    1:49AM Dendreon announces data on PROVENGE potency and long-term immune responses in androgen-dependent prostate cancer (DNDN) 17.99 : Researchers from co present data from its PROTECT (PROvenge Treatment and Early Cancer Treatment) or P-11 Phase 3 study suggesting that PROVENGE induces long-term memory immune responses that are durable and can be maintained following boosting. The results of the study also indicate that CD54 upregulation on Antigen Presenting Cells, a measure of potency, is a correlate of immune activation. P-11 is an ongoing Phase 3 clinical trial designed to evaluate the safety and biologic activity of PROVENGE in patients with non-metastatic androgen-dependent prostate cancer who have had a prostate-specific antigen recurrence following surgical removal of the prostate.